Tvardi Therapeutics (TVRD) Fundamental Analysis: Revenue, Earnings & Valuation

4.02 / 10

Netural

Fundamental scrutiny indicates moderate standing (4.0/10). Favorable drivers: Interest coverage ratio (EBIT / Interest expense) (%) and PB-ROE, balanced by issues in Asset-MV. Investment outlook: constrained.

Analysis Checks(9/10)

Revenue-MV

Value-0.18

Score3/3

Weight45.51%

1M Return7.95%

Total operating revenue (YoY growth rate %)

Value142.08

Score2/3

Weight1.83%

1M Return0.41%

Inventory turnover ratio

Value98.02

Score2/3

Weight-4.77%

1M Return-1.19%

Profit-MV

Value0.62

Score2/3

Weight19.86%

1M Return4.10%

PB-ROE

Value-0.45

Score2/3

Weight21.92%

1M Return4.39%

Fixed assets turnover ratio

Value8528.00

Score3/3

Weight3.32%

1M Return0.75%

Interest coverage ratio (EBIT / Interest expense) (%)

Value39.04

Score2/3

Weight-4.42%

1M Return-1.07%

Operating revenue (YoY growth rate %)

Value185.72

Score2/3

Weight3.05%

1M Return0.68%

Cost of sales ratio (%)

Value71.86

Score2/3

Weight-5.55%

1M Return-1.40%

Asset-MV

Value-0.72

Score1/3

Weight19.25%

1M Return3.90%

Is TVRD undervalued or overvalued?

TVRD scores 4.02/10 on fundamentals and holds a Fair valuation at present. Backed by its -237.81% ROE, 0.00% net margin, -1.53 P/E ratio, 1.33 P/B ratio, and 78.46% earnings growth, these metrics solidify its Netural investment rating.